Isaac Cheng - 06 Jan 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Net transactions value: +$124,982
Form type: 4
Filing time: 10 Jan 2022, 19:35:56 UTC
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Conversion of derivative security		+1,409,035			1,409,035	06 Jan 2022	See Footnote	F1, F2
transaction	AMLX	Common Stock	Conversion of derivative security		+6,410,964	+455%		7,819,999	06 Jan 2022	See Footnote	F1, F2
transaction	AMLX	Common Stock	Conversion of derivative security		+974,107	+12%		8,794,106	06 Jan 2022	See Footnote	F1, F2
transaction	AMLX	Common Stock	Conversion of derivative security		+1,621,544	+18%		10,415,650	06 Jan 2022	See Footnote	F1, F2
transaction	AMLX	Common Stock	Purchase	$124,982	+6,578		$19.00	6,578	06 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Series A Preferred Stock	Conversion of derivative security	$0	-1,409,035	-100%	$0.000000^*	0	06 Jan 2022	Common Stock	1,409,035		See Footnote	F1, F2
transaction	AMLX	Series B Preferred Stock	Conversion of derivative security	$0	-6,410,964	-100%	$0.000000^*	0	06 Jan 2022	Common Stock	6,410,964		See Footnote	F1, F2
transaction	AMLX	Series C-1 Preferred Stock	Conversion of derivative security	$0	-974,107	-100%	$0.000000^*	0	06 Jan 2022	Common Stock	974,107		See Footnote	F1, F2
transaction	AMLX	Series C-2 Preferred Stock	Conversion of derivative security	$0	-1,621,544	-100%	$0.000000^*	0	06 Jan 2022	Common Stock	1,621,544		See Footnote	F1, F2
transaction	AMLX	Stock Option (Right to Buy)	Award	$0	+8,400		$0.000000	8,400	06 Jan 2022	Common Stock	8,400	$19.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
F2	These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
F3	This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.